| DC10647 |
EPZ015938(pemrametostat)
Featured
|
GSK3326595(EPZ015938) is the first-in-class protein arginine methyltransferase-5 (PRMT5) inhibitor. |
|
| DC2070 |
GSK690693
Featured
|
GSK690693 is a pan-Akt inhibitor targeting Akt1, Akt2 and Akt3 with IC50 of 2 nM, 13 nM, and 9 nM, respectively. |
|
| DC7812 |
GSK923295
Featured
|
GSK923295 is a first-in-class, specific allosteric inhibitor of CENP-E kinesin motor ATPase with Ki of 3.2 nM, and less potent to mutant I182 and T183. |
|
| DC10033 |
H3B-6527
Featured
|
H3B-6527 is an orally bioavailable inhibitor of human fibroblast growth factor receptor 4 (FGFR4), with potential antineoplastic activity. |
|
| DC8768 |
HMN-214
Featured
|
HMN-214(IVX214) is a potent PLK1 inhibitor an average IC50 of 0.12 μM. |
|
| DC11262 |
IACS-010759
Featured
|
IACS-010759 (IACS010759) is a small molecule inhibitor of mitochondrial oxidative phosphorylation (OXPHOS), targets complex I of the mitochondrial electron transport chain. |
|
| DC11303 |
CT7001 hydrochloride
Featured
|
ICEC0942 is a selective CDK7 inhibitor, with IC50s of 41 nM and 578 nM for CDK7/CycH/MAT1 and CDK2/cycE1, respectively. |
|
| DC3130 |
ICG-001
Featured
|
ICG-001 is a small-molecule antagonist of b-catenin/TCF-mediated transcription (IC50 = 3 uM) and specifically downregulates the expression of a subset of b-catenin/TCF-responsive genes. ICG-001 binds specifically to cyclic AMP response element-binding pro |
|
| DC8111 |
Idarubicin Hydrochloride
Featured
|
Idarubicin Hcl is an anthracycline antibiotic and a DNA topoisomerase II (topo II) inhibitor. |
.gif)
|
| DC10538 |
IDH-305
Featured
|
IDH305 is an inhibitor of the citric acid cycle enzyme isocitrate dehydrogenase [NADP] cytoplasmic (isocitrate dehydrogenase 1; IDH1) with mutations at residue R132 (IDH1(R132)), with potential antineoplastic activity. |
|
| DC10098 |
IDO-IN-1
Featured
|
IDO-IN-1 is an indoleamine-2,3-dioxygenase (IDO) inhibitor with IC50 of 59 nM, shows activity in Hela cell (IC50=12 nM). |
|
| DC9014 |
Ifosfamide |
Ifosfamide is a nitrogen mustard alkylating agent used in the treatment of cancer. |
|
| DC4181 |
Imatinib mesylate
Featured
|
Imatinib Mesylate is orally bioavailability mesylate salt of Imatinib, which is a multi-target inhibitor of v-Abl, c-Kit and PDGFR with IC50 of 0.6 μM, 0.1 μM and 0.1 μM, respectively. |
|
| DC10406 |
Imisopasem manganese |
Imisopasem manganese (M40403) is a stable non-peptidyl mimetic of manganese superoxide MnSOD. |
|
| DC10918 |
INCB053914 |
INCB053914 (INCB-053914) is a novel potent, and selective ATP-competitive, pan-PIM kinase inhibitor with IC50 of 0.24/30.0/0.12 nM for PIM1/2/3, respectively. |
|
| DC7167 |
Capmatinib(INCB28060)
Featured
|
INCB28060 is a novel orally active inhibitor (IC50=0.13 nM) of c-MET kinase. |
|
| DC7429 |
INCB 8761
Featured
|
INCB8761(PF-4136309) is a potent, Selective, and orally bioavailable CCR2 antagonist. |
|
| DC7171 |
INK-128(Sapanisertib)
Featured
|
INK 128 is a potent and selective mTOR inhibitor with IC50 of 1 nM; >200-fold less potent to class I PI3K isoforms. |
|
| DC5072 |
Duvelisib (IPI-145, INK1197)
Featured
|
Duvelisib (IPI-145) is a selective inhibitor of the p110δ isoform, exhibiting IC50 values of 2.5 nM, 27.4 nM, 85 nM, and 1602 nM for p110δ, p110γ, p110β, and p110α, respectively, highlighting its specificity and potency. |
|
| DC9829 |
IPI-549
Featured
|
IPI-549 is an orally administered immuno-oncology development candidate that selectively inhibits PI3K-gamma. |
|
| DC5107 |
SB-715992 (Ispinesib)
Featured
|
Ispinesib (SB 715992) is a potent mitotic kinesin KSP (Eg5) inhibitor with a Ki and an IC50 of 0.6 and 4.1 nM, respectively. |
.gif)
|
| DC12378 |
Itacitinib(INCB039110)
Featured
|
Itacitinib is a potent and selective inhibitor of JAK1, with >20-fold selectivity for JAK1 over JAK2 and >100-fold over JAK3 and TYK2; Itacitinib is used in the research of myelofibrosis. |
|
| DCAPI1510 |
Ixabepilone
Featured
|
Ixabepilone (Azaepothilone B; BMS 247550) is an epothilone B analog and nontaxane microtubule-stabilizing compound with clinical activity in a range of solid tumors. |
|
| DC7175 |
JNJ-26854165 (Serdemetan)
Featured
|
JNJ-26854165 (Serdemetan) acts as a HDM2 ubiquitin ligase antagonist and also induces early apoptosis in p53 wild-type cells, inhibits cellular proliferation followed by delayed apoptosis in the absence of functional p53. |
|
| DC7177 |
JNJ 38877605
Featured
|
JNJ-38877605 is an ATP-competitive inhibitor of c-Met with IC50 of 4 nM, 600-fold selective for c-Met than 200 other tyrosine and serine-threonine kinases. |
|
| DC9272 |
K 858
Featured
|
K 858 is an ATP-uncompetitive mitotic kinesin Eg5 inhibitor, which does not effect microtubule dynamics. |
|
| DC8247 |
KNK437
Featured
|
KNK437 is a pan-HSP inhibitor, which inhibits the synthesis of inducible HSPs, including HSP105, HSP72, and HSP40. |
|
| DC10487 |
KO947
Featured
|
KO-947 is a small molecule inhibitor of extracellular-signal-regulated kinases 1 and 2 (ERK1/2), as a potential treatment for cancers in which the mitogen activated protein kinase (MAPK) pathway. |
|
| DC9788 |
KP1019(FFC14A) |
KP1019 (FFC14A) is just the second ruthenium-based anticancer agent after NAMI-A which was developed to the stage of clinical trials. |
|
| DC7067 |
KPT-330(Selinexor)
Featured
|
KPT-330, analog of KPT-185, is an orally bioavailable selective CRM1 inhibitor. |
|
